United States

+1 877 796-6397 (Toll Free)

+1 832 582-8590

sales@selleckchem.com

Europe

+49 89 96057094

+49 89 96057095

eu.order@selleckchem.com

Selleckchem.com

Compound Libraries

Selleck products have been cited in over 330 studies from top scientific journals (Science, Nature and Cell)!

Nature, 2020, 580(7801):124-129
Nature, 2020, 580(7803):391-395
Nature, 2020, 582(7811):289-293
Nature, 2020, 10.1038/s41586-020...
Nature, 2020, 580(7804):517-523
Nature, 2020, 10.1038/s41586-020...
Nature, 2020, 10.1038/s41586-020...
Nature, 2020, 578(7795):444-448
Nature, 2020, 577(7791):537-542
Nature, 2020, 580(7802):257-262
Nature, 2020, 579(7798):284-290
Nature, 2020, 579(7797):136-140
Nature, 2020, 580(7801):147-150
Nature, 2020, 578(7794):296-300
Nature, 2020, 580(7801):136-141
Nature, 2020, 579(7797):118-122
Nature, 2020, 10.1038/s41586-020...
Nature, 2020, 577(7788):109-114
Nature, 2020, 577(7788):115-120
Nature, 2019, 575(7781):203-209
Nature, 2019, 575(7783):523-527
Nature, 2019, 74(7779):571-574
Nature, 2019, 10.1038/s41586-019...
Nature, 2019, 573(7775):595-599
Nature, 2019, 573(7775):539-545
Nature, 2019, 571(7763):127-131
Nature, 2019, 573(7774):421-425
Nature, 2019, 573(7774):439-444
Nature, 2019, 10.1038/s41586-019...
Nature, 2019, 569(7755):270-274
Nature, 2019, 572(7768):254-259
Nature, 2019, 10.1038/s41586-019...
Nature, 2019, 572(7769):335-340
Nature, 2019, 572(7770):538-542
Nature, 2019, 569(7757):509-513
Nature, 2019, 569(7756):423-427
Nature, 2019, 567(7748):405-408
Nature, 2019, 566(7743):270-274
Nature, 2019, 566(7744):344-349
Science, 2019, 364(6447)
Science, 2019, 365(6454)
Science, 2019, 364(6441)
Science, 2019, 363(6434)
Science, 2019, 363(6429)
Cell, 2020, 181(3):621-636.e22
Cell, 2020, 180(6):1081-1097.e24
Cell, 2020, 180(6):1198-1211.e19
Cell, 2020, 181(2):424-441.e21
Cell, 2020, 181(3):637-652.e15
Cell, 2020, S0092-8674(20)30623-1
Cell, 2020, 181(7):1518-1532.e14
Cell, 2020, 181(7):1596-1611.e27
Cell, 2020, 180(1):64-78.e16
Cell, 2019, 179(6):1276-1288
Cell, 2019, 179(6):1306-1318
Cell, 2019, 179(3):687-702
Cell, 2019, 178(2):361-373
Cell, 2019, 176(1-2):144-153
Cell, 2019, 178(6):1421-1436
Cell, 2019, 177(5):1262-1279
Cell, 2019, 176(4):687-701
Cell, 2019, 178(5):1115-1131
...

Selleck Compound Libraries have been cited in over 500 studies!

Nature,2020,582(7811):289-293
Blood,2020,21;135(21):1870-1881
Cell Res,2020,27;1-16
Cancer Res,2020,15;80(4):832-842
Cancer Res,2020,1;80(7):1387-1400
Eur J Pharm Sci,2020,15;142:105088
Med Mycol,2020,1;58(4):493-504
Acta Pharmacol Sin,2020,41(3):423-431
J Hepatol,2020,72(1):104-118
Eur J Immunol,2020,50(1):73-85
Virology,2020,541:41-51
Antiviral Res,2020,173:104650
EBioMedicine,2020,51:102570
Biochem Biophys Res Commun,2020,1...
Cell Signal,2020,67:109508
Cancer Lett,2020,1;470:161-169
Breast Cancer Res Treat,2020,179(3):615-629
Stem Cell Reports,2020,10;14(3):478-492
Cancer Cell,2020,10;37(2):200-215.e5
Cell Syst,2020,25;10(3):240-253.e6
Bioorg Med Chem,2020,1;28(7):115372
Am J Cancer Res,2020,1;10(2):507-522
Bioorg Chem,2020,99:103847
Pancreas,2020,49(2):290-299
J Exp Clin Cancer Res,2020,10;39(1):62
Nat Cell Biol,2020,22(2):151-158
Eur J Med Chem,2020,15;192:112175
PLoS One,2020,30;15(1):e0228189
Sci Rep,2020,7;10(1):2132
J Am Soc Nephrol,2020,31(2):374-391
Am J Cancer Res,2020,1;10(3):856-869
Cell Signal,2020,70:109574
BMC Plant Biol,2020,15;20(1):158
Theranostics,2020,10;10(8):3366-3381
Nat Methods,2020,17(3):302-310
ACS Infect Dis,2020,13;6(3):467-478
Cancer Lett,2020,28;469:195-206
Front Oncol,2020,11;10:117
Cell Metab,2020,3;31(3):564-579.e7
EMBO Mol Med,2020,6;12(3):e10419
Mol Cell,2020,7;S1097-2765(20)30269-0
Nat Commun,2020,21;11(1):1009
Nat Commun,2020,14;11(1):1792
Nat Commun,2020,29;11(1):2086
J Exp Clin Cancer Res,2020,14;39(1):88
Cell Death Dis,2020,2;11(3):158
Cell Death Dis,2020,18;11(5):381
Signal Transduct Target Ther,2020,4;5:20
Mol Ther Oncolytics,2020,30;17:169-179
Cell Chem Biol,2020,20;27(2):197-205.e6
Cell Chem Biol,2020,16;27(1):94-104.e5
Cancer Discov,2020,29;CD-19-0789
Mol Cancer Ther,2020,5;molcanther...
Hum Mol Genet,2020,27;29(5):756-765
Lung Cancer,2020,145:27-32
J Virol,2020,1;94(12):e00100-20
Antimicrob Agents Chemother,2020,4...
Toxicol Sci,2020,1;174(2):218-240
Int J Mol Sci,2020,27;21(7):2327
Int J Mol Sci,2020,18;21(8):2825
Sci Rep,2020,15;10(1):684
Sci Rep,2020,24;10(1):5318
Sci Rep,2020,18;10(1):8159
Int J Biol Sci,2020,25;16(11):1774-1784
Front Microbiol,2020,21;10:2936
J Biol Chem,2020,27;jbc.RA120.12981
Breast Cancer Res Treat,2020,179(2):337-347
Life Sci,2020,15;251:117627
J Biomol Struct Dyn,2020,13;1-10
J Biomol Struct Dyn,2020,20;1-19
J Biomol Struct Dyn,2020,20;1-11
Biol Reprod,2020,25;ioaa062
Drug Des Devel Ther,2020,24;14:745-755
SLAS Discov,2020,22;2472555220922475
SLAS Discov,2020,22;2472555220924478
Hum Cell,2020,33(1):283-290
Hum Cell,2020,33(2):427-436
Acta Derm Venereol,2020,12;100(5):adv00055
J Neurooncol,2020,147(1):25-35
J Allergy Clin Immunol,2020,21;S0091-6749...
J Comput Aided Mol Des,2020,34(7):731-746
NPJ Precis Oncol,2020,19;4:12
Cell,2019,7;176(4):687-701.e5
Endocr Relat Cancer,2019,1;26(4):437-449
BMC Cancer,2019,24;19(1):102
Antimicrob Agents Chemother,2019,29;63(2)...
Mol Cancer Ther,2019,18(3):667-679
J Exp Clin Cancer Res,2019,6;38(1):56
Anal Biochem,2019,15;569:46-52
Cancer Manag Res,2019,13;11:8391-8405
Clin Cancer Res,2019,15;25(14):4530-4541
Breast Cancer Res Treat,2019,178(2):263-274
...

Q1 How fast can you publish papers with Selleck Compound Libraries?

Average time to get accepted publication with **Selleck Compound Libraries** is only **18 months**! Saving your time, compared to other methods, with article impacts averages **7.32**. **Quick**, **easy**, and **efficient** way to get your article published.

Q2 What is the probability of using the Selleck Compound Library to screen the target compound?

For every **100 Selleck compounds** used for preliminary screening, an average of **five target bioactive compounds** can be obtained. In most cases, the greater the number of compounds screened, the greater the probability of obtaining the target active compound.

Following are examples of articles screened using Selleck Compound Libraries:

Academic institution	Journal	PMID	Selleck Compound Library	Total number of screening compounds	Number of Target bioactive compounds	Research area
The Third Xiangya Hospital of Central South University, China	International Journal of Biological Sciences	30263005	**Natural Product Library**	**10**	**1**	Cancer
King Saud University, Kingdom of Saudi Arabia	Stem Cell Research & Therapy	30463599	**Stem Cell Signaling Compound Library**	**73**	**11**	Cancer
Xuanwu Hospital of Capital Medical University, China	Protein & Cell	30069858	**Natural Product Library**	**133**	**10**	Anti-aging
Department of Biology, Stanford University, USA	Cell Reports	30726737	**Customize Library**	**261**	**7**	Ferroptosis
University of Luxembourg, Luxembourg	Journal of Experimental & Clinical Cancer Research	30728057	**Kinase Inhibitor Library**	**274**	**8**	Cancer
University of Maryland, Maryland	Cancer Immunology Research	28775208	**Inhibitor Library**	**484**	**44**	Cancer
Jinan University, Guangzhou, China	Cancer Letters	30872078	**FDA-approved Drug Library**	**616**	**2**	Cancer
National Taiwan University, Taiwan	Medical Mycology	31297540	**FDA-approved Drug Library**	**1018**	**52**	Anti-infection
UT MD Anderson Cancer Center, Houston, TX, USA	Breast Cancer Research	30845991	**Customize Library**	**1150**	**11**	Cancer
Sungkyunkwan University School of Medicine, Republic of Korea	Scientific Reports	28366931	**FDA-approved Drug Library**	**1172**	**20**	Neurological disease
German Center for Neurodegenerative Diseases, Germany	Scientific Reports	30242186	**Customize Library**	**1650**	**240**	Anti-infection
German Cancer Research Center (DKFZ) and Heidelberg University	Nature Communications	31097693	**Kinase Inhibitor Library**	**2399**	**274**	Cancer
University of Nevada, USA	The Journal of Biological Chemistry	30591588	**Natural Product Library**	**3958**	**129**	Metabolism

Q3 How long does it take to screen the compound library?

If a multichannel pipette is used for manual screening, **a student can complete an entire 96-well plate compound, provided by Selleck, in one day**. Following is an example of screening with Selleck FDA Drug Library (from PMID: 31444469):



Q4 Not sure how to use a library?

Selleck provides free technical advice and experiment design help!

Tel: (832) 582-8158

E-mail: tech@selleckchem.com



Application of FDA-approved Drug Library in antiviral

Calcium channel blockers reduce severe fever with thrombocytopenia syndrome virus (SFTSV) related fatality

This article (PMID:31444469) was published on *Journal of Cell Research* (IF=17) and took about thirteen months.

Summary

Severe fever with thrombocytopenia syndrome (SFTS) is caused by a novel phlebovirus (SFTSV), and there is no effective anti-SFTSV intervention at the present time. The author screened **700** drugs (**Selleck FDA-approved Drug Library**), and finds that calcium channel blockers(**benidipine hydrochloride, nifedipine**) can significantly inhibit SFTSV infection.

Experiment Design

1. Establish Cell Model for Screening

1. Vero cells infected with SFTSV;
2. Using automated imaging and quantitative analysis to test the percentage of SFTSV-infected cells;
3. The cell activity was measured by MTT assay.

2. High-throughput Drug Screening



Compound Library: Selleck FDA-approved Drug Library

Model: Vero cells infected with SFTSV

Indicators: Virus infection (inhibition rate) and cell cytotoxicity (survive rate)

Results: Seven drugs displayed anti-SFTSV activity in a dose-dependent manner, and benidipine hydrochloride displayed the strongest inhibitory effect.

3. Mechanism Research



Benidipine hydrochloride can significantly reduce the intracellular vRNA level of SFTSV

A retrospective clinical investigation on 2087 SFTS patients showed that nifedipine can distinctly inhibit SFTSV infection and reduce SFTS-associated CFR

Application of GPCR Compound Library in liver cancer

Inducing and exploiting vulnerabilities for the treatment of liver cancer

This article (PMID: 31578521) was published on *Nature* (IF=43) and took about fifteen months.

Summary

Liver cancer remains difficult to treat and induction of senescence may represent a promising strategy for the treatment of cancer. The authors find that inhibition of the DNA-replication kinase CDC7 induces senescence selectively in liver cancer cells by CRISPR screening, and **sertraline** combined with CDC7 inhibitor can kill hepatocellular carcinoma cells by compound screening (**Selleck GPCR Compound Library**). Further mechanistic studies have demonstrated that combination of CDC7 and mTOR inhibitors results in dramatic liver tumor growth inhibition.

Experiment Design

1. Establish Cell Model for Screening

1. Employing a CRISPR-Cas9 genetic screening using a lentiviral gRNA library in liver cancer cells to identify genes inducing senescence;
2. Using a GPCR compound library screening in Huh7 cells to identify less toxic compounds selectively killing senescent liver cancer cells.

2. High-throughput Drug Screening





Compound Library: Selleck GPCR Compound Library

Model: CRISPR-Cas9 genetic screening, Compound screening

Results: CRISPR screening suggests that CDC7 can induce senescence in liver cancer cells. Compound screening finds that XL413 and Sertraline can inhibit liver cancer cells.

3. Mechanism Research



Proliferation was inhibited in TP53 mutated liver cancer cell lines treated with XL413

Tumor-bearing mice receiving XL413 or AZD8055 showed a modest reduction in tumor volume and increased animal lifespan

FDA-approved Drug Library

Cat.No. L1300

Advantage:

√ Use the compounds screened by the FDA drug library without worrying about drug safety, since they have been approved. You can apply to skip the clinical phase I If you apply for a clinical trial for a new indication.

Description:

- A unique collection of **2,697** approved drugs for high throughput screening (HTS) and high content screening (HCS);
- All drugs were from approved institutions such as FDA, EMA, HMA, CFDA, PMDA or pharmacopoeia such as USP, BP, EP, JP, Ph. Int, etc.

Cited by 206 Publications:

Nature,2020,582(7811):289-293
Cancer Cell,2020,37(2):200-215.e5
Cell Metab,2019,7;29(5):1166-1181.e6.
Nat Med,2017,23(4):405-408
Physiol Rev,2017,1;97(3):889-938.
Cell Stem Cell,2017,4;20(5):659-674.e9.
Nat Med,2014,20(8):954-60
Cell Res,2020,27;1-16.
Nat Commun,2020,14;11(1):1792.
Cancer Res,2020,15;80(4):832-842.
Stem Cell Reports,2020,14(3):478-492
Cancer Lett,2020,469:195-206
Cell Death Dis,2020,2;11(3):158.
Signal Transduct Target Ther,2020,4;5:20.
Mol Ther Oncolytics,2020,30;17:169-179.
Stem Cell Reports,2020,14(3):478-492
Cancer Lett,2020,469:195-206
Cell Death Dis,2020,2;11(3):158.
Signal Transduct Target Ther,2020,4;5...
...

FDA-approved & Passed Phase I Drug Library

Cat.No. L3800

Advantage:

√ The drugs have been approved or confirmed to be safe by phase 1 clinical trials.

Description:

- A unique collection of **2,991** drugs that are marketed around the world or have passed clinical phase 1 and can be used for high throughput screening (HTS) and high content screening (HCS);
- Drug repurposing, the application of known drugs to treat new disease indication, holds potential of rapid clinical impact at a lower cost than de novo drug development.

Cited by 73 Publications:

Cell Metab,2019,7;29(5):1166-1181.e6.
Nat Med,2014,20(8):954-60
Nat Commun,2020,14;11(1):1792.
Cancer Res,2020,15;80(4):832-842.
Stem Cell Reports,2020,14(3):478-492
Cancer Lett,2020,469:195-206
Cell Death Dis,2020,2;11(3):158.
Signal Transduct Target Ther,2020,4;5:20.
Mol Ther Oncolytics,2020,30;17:169-179.
Cell Chem Biol,2020,20;27(2):197-205...
Cell Chem Biol,2020,16;27(1):94-104.e5.
Antimicrob Agents Chemother,2020...
Toxicol Sci,2020,1;174(2):218-240.
Int J Mol Sci,2020,18;21(8):2825.
Sci Rep,2020,24;10(1):5318.
J Biol Chem,2020,27;jbc.RA120.012981.
Breast Cancer Res Treat,2020,179(2)...
PLoS One,2020,15(1):e0228189
J Allergy Clin Immunol,2020,21;S0091...
...

Preclinical/Clinical Compound Library

Cat.No. L3900

Advantage:

√ Contains various clinically popular small molecule drugs.

Description:

- A unique collection of **2,814** preclinical and clinical compounds for high throughput screening (HTS) and high content screening (HCS);
- Related to oncology, cardiology, anti-inflammatory, immunology, neuropsychiatry, analgesia etc.

Cited by 75 Publications:

Cell Metab,2019,7;29(5):1166-1181.e6.
Nat Med,2014,20(8):954-60
Nat Commun,2020,14;11(1):1792.
Cancer Res,2020,15;80(4):832-842.
Stem Cell Reports,2020,14(3):478-492
Cancer Lett,2020,469:195-206
Cell Death Dis,2020,2;11(3):158.
Signal Transduct Target Ther,2020,4;5:20.
Mol Ther Oncolytics,2020,30;17:169-179.
Cell Chem Biol,2020,20;27(2):197-205...
Cell Chem Biol,2020,16;27(1):94-104.e5.
Antiviral Res,2020,173:104650
Antimicrob Agents Chemother,2020,4...
Toxicol Sci,2020,1;174(2):218-240.
Int J Mol Sci,2020,18;21(8):2825.
Sci Rep,2020,24;10(1):5318.
J Biol Chem,2020,27;jbc.RA120...
Breast Cancer Res Treat,2020,179...
PLoS One,2020,15(1):e0228189
...

Popular Compound Libraries

Bioactive Compound Library-I

Cat.No. L1700

Advantage:

√ Contains various biologically active small molecule compounds.

Description:

- A unique collection of **7,120** bioactive compounds for high throughput screening (HTS) and high content screening (HCS);
- Includes most Selleck inhibitors, APIs, natural products, and chemotherapeutic agents.

Cited by 109 Publications:

Cell Metab,2020,31(3):564-579
Cell,2019,7;176(4):687-701.e5.
Cell Metab,2019,7;29(5):1166-1181.e6.
Nat Med,2017,23(4):405-408
Physiol Rev,2017,1;97(3):889-938.
Cancer Cell,2016,29(6):874-888
Nat Med,2014,20(8):954-60
Nat Commun,2020,14;11(1):1792.
EMBO Mol Med,2020,12(3):e10419
Cancer Res,2020,1;80(7):1387-1400.
Cancer Res,2020,15;80(4):832-842.
Int J Cancer,2020,10.1002/ijc.32966
Stem Cell Reports,2020,14(3):478-492
Cancer Lett,2020,469:195-206
Cell Death Dis,2020,2;11(3):158.
Signal Transduct Target Ther,2020,4;5:20.
Mol Ther Oncolytics,2020,30;17:169-179.
Cell Chem Biol,2020,20;27(2):197-205.e6.
Cell Chem Biol,2020,16;27(1):94-104.e5.
...

Bioactive Compound Library- Ⅱ

Cat.No. L1700-Ⅱ

Advantage:

√ Innovative compounds from the largest pharmaceutical company in the world, Biological activity has diversity and novelty.

Description:

- A unique collection of **5,309** bioactive compounds for high throughput screening (HTS) and high content screening (HCS).

Cited by 73 Publications:

Cell Metab,2019,7;29(5):1166-1181.e6.
Nat Med,2014,20(8):954-60
Nat Commun,2020,14;11(1):1792.
Cancer Res,2020,15;80(4):832-842.
Stem Cell Reports,2020,14(3):478-492
Cancer Lett,2020,469:195-206
Cell Death Dis,2020,2;11(3):158.
Signal Transduct Target Ther,2020,4;5:20.
Mol Ther Oncolytics,2020,30;17:169-179.
Cell Chem Biol,2020,20;27(2):197-205.e6.
Cell Chem Biol,2020,16;27(1):94-104.e5.
Antimicrob Agents Chemother,2020,4...
Toxicol Sci,2020,1;174(2):218-240.
Int J Mol Sci,2020,18;21(8):2825.
Sci Rep,2020,24;10(1):5318.
J Biol Chem,2020,27;jbc.RA120.012981.
Breast Cancer Res Treat,2020,179(2)...
PLoS One,2020,15(1):e0228189
J Allergy Clin Immunol,2020,21;S0091...
...

Kinase Inhibitor Library

Cat.No. L1200

Advantage:

√ Covers most kinase targets.

Description:

- A unique collection of **1,525** kinase inhibitors for high throughput screening (HTS) and high content screening (HCS);
- Targets kinases such as EGFR, PI3K, Aurora Kinase, CDK, and MEK.

Cited by 160 Publications:

Nat Methods,2020,17(3):302-310
Cell Metab,2019,7;29(5):1166-1181.e6.
Nat Med,2017,23(4):405-408
Cancer Cell,2017,32(5):684-700
Gastroenterology,2017,153(5):1429-1443
Cancer Cell,2015,28(2):240-52
Nat Med,2014,20(8):954-60
Nat Commun,2020,14;11(1):1792.
Cell Syst,2020,10(3):240-253.e6
Cancer Res,2020,15;80(4):832-842.
Stem Cell Reports,2020,14(3):478-492
Cancer Lett,2020,469:195-206
Cell Death Dis,2020,2;11(3):158.
Signal Transduct Target Ther,2020,4;5:20.
Mol Ther Oncolytics,2020,30;17:169-179.
Cell Chem Biol,2020,16;27(1):94-104.e5.
Cell Chem Biol,2020,20;27(2):197-205...
Antimicrob Agents Chemother,2020,4...
Eur J Immunol,2020,50(1):73-85
...

Express-Pick Library

Cat.No. L3600

Advantage:

√ The core structure is diverse, and about three-quarters of the compounds have not been reported by patents or articles.

Description:

- A unique collection of **4,208** chemical compounds featured different core structures and structural diversities respectively for high throughput screening (HTS) and high content screening (HCS);
- Innovative compounds from the largest pharmaceutical company in the world.

Natural Product Library

Cat.No. L1400

Description:

- A unique collection of **2,266** natural products.

Cited by 106 Publications:

Nature,2020,582(7811):289-293	Cancer Res,2020,15;80(4):832-842.	Cell Death Dis,2020,18;11(5):381.	Cell Chem Biol,2020,16;27(1):94-104.e5.
Cell Metab,2019,7;29(5):1166-1181.e6.	Stem Cell Reports,2020,14(3):478-492	Cell Death Dis,2020,2;11(3):158.	Antimicrob Agents Chemother,2020,4...
Nat Med,2014,20(8):954-60	Cancer Lett,2020,469:195-206	Signal Transduct Target Ther,2020,4;5:20.	Toxicol Sci,2020,1;174(2):218-240.
Nat Commun,2020,14;11(1):1792.	J Exp Clin Cancer Res,2020,39(1):62	Mol Ther Oncolytics,2020,30;17:169-179.	Int J Mol Sci,2020,18;21(8):2825.
Theranostics,2020,10(8):3366-3381	J Exp Clin Cancer Res,2020,14;39(1):88.	Cell Chem Biol,2020,20;27(2):197-205.e6.	...

Human Endogenous Metabolite Compound Library

Cat.No. L4500

Description:

- A unique collection of **541** human endogenous metabolites for high-throughput screening and high content screening (HCS);
- Used for metabonomics and metabolism-related research;
- For studying human metabolic diseases, exploring the pathogenesis of diseases such as cancer,and opening noval therapeutic ways.

Cited by 73 Publications:

Cell Metab,2019,7;29(5):1166-1181.e6.	Cancer Lett,2020,469:195-206	Cell Chem Biol,2020,16;27(1):94-104.e5.	J Biol Chem,2020,27;jbc.RA120.012981.
Nat Med,2014,20(8):954-60	Cell Death Dis,2020,2;11(3):158.	Antimicrob Agents Chemother,2020,4...	Breast Cancer Res Treat,2020,179(2)...
Nat Commun,2020,14;11(1):1792.	Signal Transduct Target Ther,2020,4;5:20.	Toxicol Sci,2020,1;174(2):218-240.	PLoS One,2020,15(1):e0228189
Cancer Res,2020,15;80(4):832-842.	Mol Ther Oncolytics,2020,30;17:169-179.	Int J Mol Sci,2020,18;21(8):2825.	bioRxiv,2020,doi:10.1101/2020.05.26...
Stem Cell Reports,2020,14(3):478-492	Cell Chem Biol,2020,20;27(2):197-205...	Sci Rep,2020,24;10(1):5318.	...

Fragment Library

Cat.No. L1600

Description:

- A unique collection of **1,015** Fragment compounds for Fragment-Based Drug Discovery (FBDD);
- FBDD has emerged as an alternative approach for high-throughput screening (HTS) in discovering drug;
- These fragments with low molecular weight are extremely suitable for screening clinical candidates with good drug-like properties, and more and more compounds discovered by FBDD are entering the clinic.

Popular Compound Libraries

Covalent Inhibitor Library

Cat.No. L5800

Description:

- A unique collection of **81** covalent Inhibitors for high throughput screening (HTS) and high content screening (HCS);
- Covalent inhibitors have excellent pharmacokinetic characteristics,and can overcome the resistance generated by mutations.

Cited by 73 Publications:

Cell Metab,2019,7;29(5):1166-1181.e6.	Cancer Lett,2020,469:195-206	Cell Chem Biol,2020,16;27(1):94-104.e5.	J Biol Chem,2020,27;jbc.RA120.012981.
Nat Med,2014,20(8):954-60	Cell Death Dis,2020,2;11(3):158.	Antimicrob Agents Chemother,2020,4...	Breast Cancer Res Treat,2020,179(2)...
Nat Commun,2020,14;11(1):1792.	Signal Transduct Target Ther,2020,4;5:20.	Toxicol Sci,2020,1;174(2):218-240.	PLoS One,2020,15(1):e0228189
Cancer Res,2020,15;80(4):832-842.	Mol Ther Oncolytics,2020,30;17:169-179.	Int J Mol Sci,2020,18;21(8):2825.	J Allergy Clin Immunol,2020,21...
Stem Cell Reports,2020,14(3):478-492	Cell Chem Biol,2020,20;27(2):197-205.e6.	Sci Rep,2020,24;10(1):5318.	...

Ferroptosis Compound Library

Cat.No. L6400

Description:

- A unique collection of **547** ferroptosis related compounds for high throughput screening (HTS) and high content screening (HCS);
- Targets iron, ROS, p53, NRF2 etc.;
- Some compounds have been approved by the FDA.

Cited by 73 Publications:

Cell Metab,2019,7;29(5):1166-1181.e6.	Cell Death Dis,2020,2;11(3):158.	Toxicol Sci,2020,1;174(2):218-240.	J Allergy Clin Immunol,2020,21;S0091...
Nat Med,2014,20(8):954-60	Signal Transduct Target Ther,2020,4;5:20.	Int J Mol Sci,2020,18;21(8):2825.	bioRxiv,2020,doi:10.1101/2020.05.26...
Nat Commun,2020,14;11(1):1792.	Mol Ther Oncolytics,2020,30;17:169-179.	Sci Rep,2020,24;10(1):5318.	Genome Biol,2019,20(1):253
Cancer Res,2020,15;80(4):832-842.	Cell Chem Biol,2020,20;27(2):197-205.e6.	J Biol Chem,2020,27;jbc.RA120.012981.	Sci Adv,2019,5(6):eaav9784
Stem Cell Reports,2020,14(3):478-492	Cell Chem Biol,2020,16;27(1):94-104.e5.	Breast Cancer Res Treat,2020,179(2)...	Cell Rep,2019,5;26(6):1544-1556.e8.
Cancer Lett,2020,469:195-206	Antimicrob Agents Chemother,2020...	PLoS One,2020,15(1):e0228189	...

Highly Selective Inhibitor Library

Cat.No. L3500

Description:

- A unique collection of **339** validated highly selective inhibitors with covering over 123 targets;
- Selectivity is at least 100-fold higher relative to non-primary target(s);
- Each compound was selected based on its ability to principally interact with a single target, leading to minimal off-target activity;
- Targets cover a wide variety of signaling pathways, including PI3K/Akt, MAPK, PTK, JAK, apoptosis, and others.

Cited by 76 Publications:

Cell Metab,2019,7;29(5):1166-1181.e6.	Cancer Res,2020,15;80(4):832-842.	Cell Chem Biol,2020,20;27(2):197-205.e6.	J Biol Chem,2020,27;jbc.RA120.012981.
Nat Med,2017,23(4):405-408	Stem Cell Reports,2020,14(3):478-492	Cell Chem Biol,2020,16;27(1):94-104.e5.	Breast Cancer Res Treat,2020,179(2)...
Nat Med,2014,20(8):954-60	Cancer Lett,2020,469:195-206	Antimicrob Agents Chemother,2020,4...	PLoS One,2020,15(1):e0228189
Blood,2020,21;135(21):1870-1881.	Cell Death Dis,2020,2;11(3):158.	Toxicol Sci,2020,1;174(2):218-240.	bioRxiv,2020,doi:10.1101/2020.05.26...
Mol Cell,2020,7;S1097-2765(20)30269-0.	Signal Transduct Target Ther,2020,4;5:20.	Int J Mol Sci,2020,18;21(8):2825.	J Allergy Clin Immunol,2020,21;S0091...
Nat Commun,2020,14;11(1):1792.	Mol Ther Oncolytics,2020,30;17:169-179.	Sci Rep,2020,24;10(1):5318.	...

Clinical and FDA-approved Related

FDA-approved Drug Library
Cat.No. L1300

A unique collection of **2,697** approved drugs

FDA-approved & Passed Phase I Drug Library
Cat.No. L3800

A unique collection of **2,991** drugs that are marketed around the world or have passed clinical phase 1

Preclinical/Clinical Compound Library
Cat.No. L3900

A unique collection of **2,814** preclinical and clinical compounds

FDA-approved Anticancer Drug Library
Cat.No. L8000

NEW

A unique collection of **1,567** approved drugs with anticancer activity

Bioactive Compound Libraries

Bioactive Compound Library-I
Cat.No. L1700

A unique collection of **7,120** bioactive compounds

Bioactive Compound Library- Ⅱ
Cat.No. L1700- Ⅱ

A unique collection of **5,309** bioactive compounds

Express-Pick Library
Cat.No. L3600

A unique collection of **4,208** chemical compounds featured different core structures

HTS Library for Drug Discovery
Cat.No. L5000

A unique collection of **99,040** compounds features numerous structurally diverse compounds

Inhibitor Related

Kinase Inhibitor Library
Cat.No. L1200

A unique collection of **1,525** kinase inhibitors

Highly Selective Inhibitor Library
Cat.No. L3500

A unique collection of **339** validated highly selective inhibitors

Inhibitor Library
Cat.No. L1100

A unique collection of **3,456** small molecule inhibitors

Inhibitor Related

Protease Inhibitor Library
Cat.No. L2500

A unique collection of **227** protease-related small molecule inhibitors

Protein-protein Interaction Inhibitor Library
Cat.No. L8100

NEW

A unique collection of **188** protein-protein Interaction(PPI) Inhibitors

Tyrosine Kinase Inhibitor Library
Cat.No. L1800

A unique collection of **390** tyrosine kinase inhibitors

Natural Product and Medicine Food Homology Related

Natural Product Library
Cat.No. L1400

A unique collection of **2,266** natural products

Alkaloid Compound Library
Cat.No. L7900

NEW

A unique collection of **269** alkaloid compounds

Flavonoid Compound Library
Cat.No. L7700

NEW

A unique collection of **185** flavonoid compounds

Medicine Food Homology Compound Library
Cat.No. L6800

A unique collection of **376** medicine food homology compounds

Natural Organic Compound Library
Cat.No. L7600

NEW

A unique collection of **1,127** plant-derived natural organic compounds

Traditional Chinese Medicine Library
Cat.No. L8300

NEW

A unique collection of **1,044** traditional chinese medicine(TCM) monomer compounds

Metabolism Related

Human Endogenous Metabolite Compound Library
Cat.No. L4500

541 small collections of human endogenous metabolites

Glutamine Metabolism Compound Library
Cat.No. L6900

A unique collection of **236** glutamine metabolism related compounds

Metabolism Related

Gut Microbial Metabolite Library
Cat.No. L8400 NEW
A unique collection of **91** gut microbial metabolites

Metabolism Compound Library
Cat.No. L3700
A unique collection of **2,024** metabolically related bioactive compounds

Cell Death Related

Apoptosis Compound Library
Cat.No. L3300
A unique collection of **978** small molecules used for apoptosis research

Autophagy Compound Library
Cat.No. L2600
A unique collection of **998** small molecules with autophagy-inducing or autophagy-inhibiting activity

Ferroptosis Compound Library
Cat.No. L6400
A unique collection of **547** ferroptosis related compounds

Pyroptosis Compound Library
Cat.No. L7400 NEW
A unique collection of **441** pyroptosis related compounds

By Signaling Pathway

Angiogenesis Related compound Library
Cat.No. L5200
A unique collection of **232** small molecules associated with angiogenesis

Antioxidant Compound Library
Cat.No. L6500
A unique collection of **426** anti-oxidation related compounds

Cell Cycle Compound Library
Cat.No. L5100
A unique collection of **120** small molecule compounds used for cell cycle and related diseases research

Cytoskeletal Signaling Pathway Compound Library
Cat.No. L6300 NEW
A unique collection of **184** cytoskeletal signaling related compounds

DNA Damage/DNA Repair Compound Library
Cat.No. L4600
A unique collection of **511** small molecules used for DNA Damage and Repair research

By Signaling Pathway

Epigenetics Compound Library
Cat.No. L1900
A unique collection of **606** compounds with biological activity used for epigenetic research and associated assays

GPCR Compound Library
Cat.No. L2200
A unique collection of **1,086** small molecules targeting G protein coupled receptors

HIF-1 Signaling Pathway Compound Library
Cat.No. L6100 NEW
A unique collection of **447** HIF-1 signaling pathway compounds

Histone Modification Compound Library
Cat.No. L4900
A unique collection of **199** bioactive compounds associated with histone modifications

Ion Channel Ligand Library
Cat.No. L2700
A unique collection of **231** small molecule modulators used for Ion channel research

JAK/STAT Compound Library
Cat.No. L5400
A unique collection of **50** small molecules used for research in JAK-STAT signaling pathway

MAPK Inhibitor Library
Cat.No. L3400
A unique collection of **175** small molecule inhibitors used for MAPK signaling research

Methylation Compound Library
Cat.No. L6600
A unique collection of **112** methylation related compounds

NF- κ B Signaling Compound Library
Cat.No. L5500
A unique collection of **310** small molecules used for NF-κB signaling pathway research

PI3K/Akt Inhibitor Library
Cat.No. L2800
A unique collection of **261** small molecule inhibitors used for PI3K/Akt/mTOR pathway research

Stem Cell Signaling Compound Library
Cat.No. L2100
A unique collection of **491** bioactive compounds associated with stem cell signaling pathways

TGF-beta/Smad Compound Library
Cat.No. L5600
A unique collection of **105** small molecules with biological activity used for TGF-beta/Smad pathway research

Ubiquitination Compound Library
Cat.No. L6000
A unique collection of **151** small molecules for Ubiquitination related research

By Disease

Anti-Aging Compound Library
Cat.No. L6200 NEW
A unique collection of **1,499** anti-aging compounds used for aging related research

Anti-alzheimer Disease Compound Library
Cat.No. L5900
A unique collection of **485** small molecules for exploring the mechanism of alzheimer's disease

Anti-cancer Compound Library
Cat.No. L3000
A unique collection of **3,550** anti-tumor compounds in clinical trials

Anti-cancer Compound Library (Verified by Broad Institute)
Cat.No. L7100
A unique collection of **922** compounds with anticancer activity which has been verified by broad institute

Anti-cancer Metabolism Compound Library
Cat.No. L5700
A unique collection of **194** bioactive compounds for cancer metabolism research

Anti-Cardiovascular Disease Compound Library
Cat.No. L7500 NEW
A unique collection of **700** anti-cardiovascular disease related compounds

Anti-diabetic Compound Library
Cat.No. L2900
A unique collection of **150** bioactive compounds associated with the development of diabetes

Cambridge Cancer Compound Library
Cat.No. L2300
A unique collection of **247** high value-added anticancer compounds

Obesity Compound Library
Cat.No. L6700
A unique collection of **936** compounds used for research in obesity

Small Molecule Immuno-Oncology Compound Library
Cat.No. L4800
A unique collection of **122** Immuno-Oncology small molecules

Anti-infection and Antiviral Related

Antibiotics Compound Library
Cat.No. L5300
A unique collection of **307** antibiotics

Anti-infection Compound Library
Cat.No. L3100
A unique collection of **927** anti-infection compounds

Anti-infection and Antiviral Related

Anti-parasitic Compound Library
Cat.No. L8200 NEW
A unique collection of **171** anti-parasitic compounds

Antiviral Compound Library
Cat.No. L7000
A unique collection of **347** antiviral compounds

Macrocyclic Compound Library
Cat.No. L7300
A unique collection of **106** macrocyclic compounds

Nucleoside Analogue Library
Cat.No. L7200
A unique collection of **135** nucleoside analogues

Neuronal and Immunology Related

CNS-Penetrant Compound Library
Cat.No. L4700
A unique collection of **307** CNS-Penetrant compounds

Immunology/Inflammation Compound Library
Cat.No. L4100
A unique collection of **1,834** active compounds associated with immune inflammation

Neuronal Signaling Compound Library
Cat.No. L4000
A unique collection of **1,093** biologically active compounds associated with neural signaling pathways

Fragment and Covalent Related

Covalent Inhibitor Library
Cat.No. L5800
A unique collection of **81** covalent Inhibitors

Drug-like Compound Library
Cat.No. L7800 NEW
A unique collection of **2,081** drug-like compounds

Fragment Library
Cat.No. L1600
A unique collection of **1,015** Fragment compounds for Fragment-Based Drug Discovery (FBDD)

Customize Library

No suitable compound library? The exclusive compound library can be customized according to your needs.

You could select:


Specific Compounds


Quantity


96 or 384 well Plate


Dry/solid or DMSO solution

Please contact us at info@selleckchem.com to customize your library.